These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28149650)

  • 1. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review.
    Gastaldi G; Goossens N; Clément S; Negro F
    J Adv Res; 2017 Mar; 8(2):149-159. PubMed ID: 28149650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy.
    Mazzaro C; Quartuccio L; Adinolfi LE; Roccatello D; Pozzato G; Nevola R; Tonizzo M; Gitto S; Andreone P; Gattei V
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
    Ferreira J; Bicho M; Serejo F
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus and type 2 diabetes.
    Negro F; Alaei M
    World J Gastroenterol; 2009 Apr; 15(13):1537-47. PubMed ID: 19340895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.
    Salama II; Raslan HM; Abdel-Latif GA; Salama SI; Sami SM; Shaaban FA; Abdelmohsen AM; Fouad WA
    World J Hepatol; 2022 Jun; 14(6):1053-1073. PubMed ID: 35978668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current understanding of insulin resistance in hepatitis C.
    Kaddai V; Negro F
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):503-16. PubMed ID: 21780897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
    Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A
    Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
    Honma Y; Shibata M; Morino K; Koya Y; Hayashi T; Ogino N; Kusanaga M; Oe S; Miyagawa K; Abe S; Tabaru A; Harada M
    Dig Dis Sci; 2023 Feb; 68(2):685-698. PubMed ID: 36100828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management.
    Nevola R; Acierno C; Pafundi PC; Adinolfi LE
    Minerva Med; 2021 Apr; 112(2):188-200. PubMed ID: 33205641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C and diabetes: the inevitable coincidence?
    Lonardo A; Adinolfi LE; Petta S; Craxì A; Loria P
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):293-308. PubMed ID: 19344243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection?
    Naing C; Mak JW; Wai N; Maung M
    Curr Diab Rep; 2013 Jun; 13(3):428-34. PubMed ID: 23463119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus, Insulin Resistance, and Steatosis.
    Kralj D; Virović Jukić L; Stojsavljević S; Duvnjak M; Smolić M; Čurčić IB
    J Clin Transl Hepatol; 2016 Mar; 4(1):66-75. PubMed ID: 27047774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus-Associated Cancers.
    Yi Z; Yuan Z
    Adv Exp Med Biol; 2017; 1018():129-146. PubMed ID: 29052135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
    Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
    Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection.
    Retamozo S; Brito-Zerón P; Quartuccio L; De Vita S; Ramos-Casals M
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1085-1101. PubMed ID: 28715943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes.
    Mihm S
    Dig Dis; 2010; 28(1):280-4. PubMed ID: 20460924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Direct-Acting Antivirals for the Treatment of Hepatitis C Virus-Associated Oral Lichen Planus: A Case Report.
    Misaka K; Kishimoto T; Kawahigashi Y; Sata M; Nagao Y
    Case Rep Gastroenterol; 2016; 10(3):617-622. PubMed ID: 27920651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update.
    Roguljic H; Nincevic V; Bojanic K; Kuna L; Smolic R; Vcev A; Primorac D; Vceva A; Wu GY; Smolic M
    Front Pharmacol; 2021; 12():678546. PubMed ID: 34045969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH.
    Koike K
    Hepatol Res; 2005 Oct; 33(2):145-50. PubMed ID: 16202646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations.
    El Kassas M; Hegazy OM; Salah EM
    World J Hepatol; 2020 Oct; 12(10):841-849. PubMed ID: 33200021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.